Safe AI in Pharmaceuticals: Validation, Data Integrity and Regulated AI in Life Sciences

This online course addresses the growing need for understanding artificial intelligence applications within pharmaceutical manufacturing and research environments. Participants will explore computerised system validation principles specifically tailored to AI implementations, examining how these systems must meet regulatory requirements while maintaining data integrity throughout their lifecycle. The programme covers essential GxP expectations for AI usage in clinical settings and manufacturing processes. Learners will discover practical approaches to ensuring inspection readiness through proper documentation and quality management practices. The course structure enables busy professionals to develop essential knowledge about AI validation frameworks and regulatory compliance without disrupting their daily responsibilities.

The training programme focuses on real-world applications of AI within life sciences organisations. Attendees will examine how data integrity principles apply to machine learning models and automated decision-making systems. The curriculum addresses clinical use cases where AI supports drug discovery, manufacturing quality control, and patient safety monitoring. Participants learn to identify potential risks associated with AI deployment and develop strategies for maintaining regulatory compliance. The course includes practical guidance on preparing for regulatory inspections, including documentation requirements and audit readiness procedures. Through interactive modules and case-based learning, participants gain confidence in applying validation and data integrity concepts to their specific organisational contexts.

Frequently asked questions

How is AI used in pharmaceuticals?

AI algorithms analyse vast datasets from clinical trials and patient records to identify potential drug candidates and predict their effectiveness. Machine learning models assist in drug discovery by modelling molecular structures and forecasting how different compounds might interact with biological targets. AI systems also monitor regulatory compliance and quality control processes throughout manufacturing by detecting anomalies in production data.

Does AI in pharma need computerised system validation?

Yes AI systems in pharmaceutical manufacturing and quality control require computerised system validation to ensure they operate correctly and consistently. Clause 7.4 of ISO 13485 specifies that computerised systems must be validated before use in regulated environments. This validation process confirms that AI applications meet specified requirements and maintain data integrity throughout their lifecycle.

What are data integrity requirements for AI systems?

Data integrity requirements for AI systems mandate that training data must be accurate representative samples of the problem domain to prevent biased or unreliable outcomes. Clause 8.2 of ISO 27001 specifies that organisations must implement controls to ensure data remains complete and accurate throughout its lifecycle. AI systems require ongoing monitoring to detect and correct data drift or corruption that could compromise system performance.

Can AI be used in pharmacovigilance case processing?

AI can assist in pharmacovigilance case processing by automatically categorising and prioritising adverse event reports based on predefined criteria. Machine learning algorithms can identify potential safety signals and flag unusual patterns in drug reaction data. The technology helps reduce manual workload for reviewers while maintaining compliance with regulatory requirements such as those outlined in ISO 13485 clause 7.5.

How do regulators view AI in clinical trials?

Regulators globally are increasingly recognising artificial intelligence as a tool that can enhance clinical trial design and data analysis. The European Medicines Agency and US FDA have issued guidance documents outlining how AI systems should be validated and documented when used in clinical research. These regulatory bodies emphasise that AI applications must maintain data integrity and transparency while ensuring patient safety remains the primary focus throughout the trial process.

What happens when a validated model is retrained?

When a validated model is retrained it processes new data to update its parameters and improve performance. The retraining process involves feeding the model fresh information so it can adjust its internal weights and biases accordingly. This helps maintain the model’s accuracy and relevance as conditions or data patterns change over time.

Is AI in drug manufacturing regulated?

AI systems used in drug manufacturing fall under existing regulatory frameworks rather than having specific AI-only regulations. The MHRA and EMA require that any AI applications in pharmaceutical production must comply with good manufacturing practice (GMP) regulations including clause 21 of the EU GMP guidelines. Companies must demonstrate that AI systems are validated, documented, and controlled according to established quality management systems.

What documentation do inspectors expect for AI systems?

Inspectors expect to see documentation covering the design, development, and deployment of AI systems including data sources and quality assessments. They require records of testing procedures, validation outcomes, and any risk assessments conducted during the system’s lifecycle. The documentation should also include details of how the AI system complies with relevant regulations such as those covering data protection and safety standards.

Does the EU AI Act apply to pharmaceutical companies?

The EU AI Act applies to pharmaceutical companies when they use AI systems in their operations. Clause 3(1)(a) of the Act covers AI systems used for clinical trials or medical device development. The regulation also applies to AI systems used for drug discovery or manufacturing processes.